ASGCT 2026: Siren Biotechnology recently has seen two INDs cleared for its AAV based gene therapy for oncology. Founder Nicole Paulk discusses how they are prepared to enter the clinic shortly
May 13
1 min read
She describes how the first trials will target glioma, a type of brain cancer, and Siren has also done work to show that the approach could be a universal therapy that may have utility against numerous cancers. Plus, how Siren did a unique crowdfunded $5 million fundraise.
Coverage brought to you by
.png){kind=logo}